Selected medication-error data from USP's MEDMARX program for 2002

Rodney W Hicks1, Diane D Cousins, Roger L Williams

  • 1Center for the Advancement of Patient Safety, United States Pharmacopeia, Rockville, MD, USA.

Abstract

Insights

In 2002, over 192,000 medication errors were reported to the MEDMARX database. Most errors did not reach patients, but 2% caused harm, highlighting the need for improved medication safety.

Area of Science:

  • Pharmacovigilance
  • Patient Safety
  • Health Informatics

Background:

  • Medication errors pose a significant threat to patient safety.
  • The MEDMARX database collects medication error data from healthcare institutions.
  • Understanding medication error trends is crucial for developing effective prevention strategies.

Purpose of the Study:

  • To analyze medication error data from USP's MEDMARX database for the year 2002.
  • To identify the scope, nature, and contributing factors of medication errors.
  • To provide insights into medication error categories, nodes, causes, and involved drug products.

Main Methods:

  • Analysis of 192,477 medication error records submitted to MEDMARX in 2002.
  • Categorization of errors based on occurrence, patient reach, and effect.
  • Examination of error nodes, types, causes, contributing factors, and drug products.

Main Results:

  • A total of 192,477 medication error records were analyzed from 482 institutions, an 82.2% increase from 2001.
  • 35% of errors did not reach the patient, 49% reached the patient, and 2% caused or may have caused harm.
  • Detailed findings on error nodes, types, causes, contributing factors, and drug products are presented.

Conclusions:

  • Analysis of over 192,000 medication error records provided comprehensive data on medication errors in 2002.
  • The findings offer valuable insights into the medication use process and potential areas for intervention.
  • This study underscores the importance of robust medication error reporting systems for enhancing patient safety.

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).